Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors

16 Jul 2024

Abstract excerpt

Background Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are found in 1% of gliomas across children and adults. TRK inhibitors are promising therapeutic agents for NTRK-fused gliomas because they are tissue agnostic and cross the blood-brain barrier (BBB). Methods We investigated twelve NGS-verified NTRK-fused gliomas from a single institute, Seoul National University Hospital. Results The patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39014476
DOI: 10.1186/s40478-024-01798-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitorsPMID 39014476Read ↗

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy TargetSemantic proximity Read ↗

NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesSemantic proximity Read ↗

TRK expressions and NTRK rearrangements in Pediatric TumorsSemantic proximity Read ↗

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric PatientsSemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical OutcomeSemantic proximity Read ↗

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse modelsSemantic proximity Read ↗

Testing algorithm for identification of patients with TRK fusion cancerSemantic proximity Read ↗

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse modelsSemantic proximity Read ↗

NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.Semantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.